1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 | [CONTINUED FROM LIC 812-C, 1 of 3]
On 06/03/2025, P1 evaluated R1 via a tele-medicine appointment, then sent a signed letter to Licensee essentially saying that while P1 was aware of what earlier transpired on 05/25/2025, they had been assigned to R1 over two years and believed R1 was “not actively suicidal.” P1 determined that one-on-one supervision was not needed, that evaluation by a psychiatrist was not needed, and that R1 should go back to independently storing and taking their own prescribed medications. Upon receipt of this letter, Licensee discontinued one-on-one supervision for R1. However, Licensee then requested from P1 an updated list of R1’s prescribed medications and an updated LIC602 Physician’s Report showing that R1 could self-manage medications (to override/overturn the earlier LIC602 completed by P3). As of 07/01/2025, Licensee had not received these documents from P1 and was thus continuing to centrally-store and manage R1’s medications.
CCLD interviewed R1 twice for this case, a few days apart, finding: To the lay observer, R1 was alert, oriented, and articulate, with no signs of memory-impairment. R1 continued to deny intent to commit suicide. However, LPA identified areas of potential concern, requiring further research, assessment, and/or education w/ R1: 1) The pharmacy prescription label on R1’s bottle of Oxycodone immediate-release tablets for pain lacked clear dosage instructions, saying instead, “Please see attached for detailed instructions.” The corresponding pharmacy paperwork that arrived with this medication also said, “Please see attached for detailed directions.” When LPA asked R1 how they typically took their Oxycodone medication, R1 gave inconsistent answers regarding the time-spacing and maximum number of tablets they would consume per typical day; 2) During his 06/27/2025 site visit, LPA observed inside R1’s room an empty bottle which once contained Oxycodone extended-release tablets for pain. The prescription label showed one tablet was to be taken twelve (12) hours apart. R1 said they took this medication just twice per day. However, per the label, sixty (60) tablets were dispensed on 06/02/2025; that R1 ran out of tablets suggests there were days earlier in the cycle when R1 consumed more than two tablets per day; 3) Regarding their as-needed Clonazepam tablets for anxiety, R1’s statements showed they did not consistently adhere to the prescribed time-spacing instructions for this medication; 4) Regarding their as-needed Hydroxyzine tablets for itching, R1’s statements showed they did not adhere to the prescribed maximum daily dose for this medication; 5) LPA observed multiple bottles of wine/liqueur near R1’s bed. Staff interviews showed a recent increase in R1’s ordering of wine/alcohol from outside sources (which have been dropped off at the facility’s front desk). Per R1’s own statements, they are nearly continuously medicated with opioids during their waking hours. P1 should clarify for Licensee if alcohol is contraindicated with R1’s current medications. [CONTINUED ON LIC 812-C, 3 of 3] |